MicroStrategy (MSTR) stock surged 30% in the past month, outperforming Bitcoin's 9.6% gain and other crypto-related stocks. Following this strong performance, Citigroup raised its price target for MicroStrategy shares to $240 and maintained a Buy rating, validating the recent momentum. The stock's leveraged exposure to Bitcoin amplifies both gains and risks, as fixed dividend obligations remain regardless of Bitcoin's price moves. Investors should consider their confidence in Bitcoin's continued rise and carefully size their positions due to the stock's volatility and leverage.
While MicroStrategy (MSTR) stock has surged 30% in the past month, Citigroup Inc. (C) trades at USD 127.66, closer to its 52-week low of USD 93.93 than its high of USD 145.67 as of Oct 02, 2026 23:13 WIB. The iShares Bitcoin Trust (IBIT), linked to crypto like MSTR, is priced at USD 48.26, well below its 52-week high of USD 71.29 but above its low of USD 33.29. On Pluang, Citigroup shows a modest 1-day gain of 0.52%, while IBIT is up 0.63%, reflecting steadier moves compared to MSTR's recent volatility.
Citigroup's strong Q2 performance, including a 12% dividend increase and a $30 billion share buyback, has led to an upgrade to hold by analyst Ian Bezek. Despite solid fundamentals, sector-wide risks from rising interest rates and a flat yield curve ...
Shares of major U.S. money-center banks declined, with Citigroup falling 4%, Bank of America down 3%, and JPMorgan Chase slipping 0.9%. Bank of America's drop follows a $39 million settlement over Merrill Lynch cash sweep accounts, but this legal iss...
Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, ...
Rocket Lab secured its largest-ever Electron launch contract with Tokyo-based Synspective for 20 missions over several years, pushing its launch backlog beyond 100 missions. This multi-year deal, combined with a new Buy rating and $105 price target f...
Citigroup maintains a 'Buy' rating for Zymeworks Inc. following its strategic acquisition of Theravance Biopharma, which aims to diversify cash flows and combine R&D with revenue-generating assets. The acquisition includes the product YUPELRI, expect...
